Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:17:1829-38.
Epub 2011 Jul 6.

High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy

Affiliations

High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy

Ahmed M Abu El-Asrar et al. Mol Vis. 2011.

Abstract

Purpose: To measure levels of high-mobility group box -1 (HMGB1) and soluble receptor for advanced glycation end products (sRAGE) in the vitreous fluid from patients with proliferative diabetic retinopathy (PDR) and to correlate their levels with clinical disease activity and the levels of the inflammatory biomarkers monocyte chemoattractant protein-1 (MCP-1), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-1β (IL-1β), and granulocyte macrophage colony-stimulating factor (GM-CSF). In addition, we examined the expression of HMGB1 in the retinas of diabetic mice.

Methods: Vitreous samples from 29 PDR and 17 nondiabetic patients were studied by enzyme-linked immunosorbent assay. Retinas of mice were examined by immunofluorescence analysis and western blotting.

Results: HMGB1 was detected in all vitreous samples and sRAGE was detected in 5 PDR samples. IL-1β was detected in 3PDR samples and GM-CSF was not detected. Mean HMGB1 levels in PDR with active neovascularization were twofold and threefold higher than that in inactive PDR and nondiabetic patients, respectively. Mean HMGB1 levels in PDR patients with hemorrhage were significantly higher than those in PDR patients without hemorrhage and nondiabetic patients (p=0.0111). There were significant correlations between levels of HMGB1 and levels of MCP-1 (r=0.333, p=0.025) and sICAM-1 (r=0.548, p<0.001). HMGB1 expression was also upregulated in the retinas of diabetic mice.

Conclusions: Subclinical chronic inflammation might contribute to the progression of PDR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Western-blotting analysis of high-mobility group box −1 (HMGB1) in mouse retina. There is a significant increase in the expression of HMGB1 in the retinas of diabetic mice (D) compared to the nondiabetic control (C). OD is optical density
Figure 2
Figure 2
Immunolocalization of high-mobility group box −1 (HMGB1) in control (upper row of panels) and diabetic (lower row of panels) retinas. Immunofluorescence using isolectin B4 as a vascular marker (red), a nuclear marker 4’,6-diamidino 2-phenylindole (DAPI), and HMGB1 antibody showed increased expression of HMGB1 in diabetic retina in comparison to the control. HMGB1 is localized mainly in ganglion cells (GC), inner nuclear layer (INL), and retinal vasculatures (arrows). Abbreviations: IPL represents inner plexiform layer; OPL represents outer plexiform layer; ONL represents outer nuclear layer.

References

    1. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS. Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450–2. - PubMed
    1. Miyamoto K, Khosrof S, Brusell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999;96:10836–41. - PMC - PubMed
    1. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11:91–9. - PubMed
    1. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw. 2006;17:155–65. - PubMed
    1. Abu el-Asrar AM, Van Damme J, Put W, Veckeneer M, Dralands L, Billiau A, Missotten L. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol. 1997;123:599–606. - PubMed

Publication types

MeSH terms